Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Authors:
- L. BarkholtLBL. Barkholt
- M. BregniMBM. Bregni
- M. RembergerMRM. Remberger
- D. BlaiseDBD. Blaise
- J. PeccatoriJPJ. Peccatori
- G. MassenkeilGMG. Massenkeil
- P. PedrazzoliP. Pedrazzoli
- A. ZambelliAZA. Zambelli
- J.-O. BayJBJ.-O. Bay
- S. FrancoisSFS. Francois
- R. MartinoRMR. Martino
- C. BengalaCBC. Bengala
Open Access
- 28 April 2006
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 17 (7) , 1134-1140
Abstract
Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres. Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3–41) months. Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), 70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%. Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.Keywords
This publication has 37 references indexed in Scilit:
- Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHDBlood, 2006
- Treatment Options in Metastatic Renal Carcinoma: An Embarrassment of RichesJournal of Clinical Oncology, 2006
- Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantationCancer, 2005
- Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago ExperienceBone Marrow Transplantation, 2004
- Prognostic Factors for Survival of Patients with Stage IV Renal Cell CarcinomaClinical Cancer Research, 2004
- Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cellsBone Marrow Transplantation, 2004
- A graft-versus-colonic cancer effect of allogeneic stem cell transplantationBone Marrow Transplantation, 2001
- Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemiaBone Marrow Transplantation, 1999
- MANIPULATION OF GRAFT-VERSUS-HOST DISEASE FOR A GRAFT-VERSUS-LEUKEMIA EFFECT AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION IN AKR MICE WITH SPONTANEOUS LEUKEMIA/LYMPHOMA1Transplantation, 1986
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979